Skip to main content
Olivia Dimmer on Muck Rack

Olivia Dimmer

As seen in: MSN, USA Today, U.S. News and World Report, Chicago Sun-Times, Detroit Free Press, Flipboard, La Voz Chicago, Phys.org, The Seattle Times, Medscape and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Olivia

Contact Olivia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immunotherapy shows long-term promise in aggressive lymphoma

|
By Olivia Dimmer, Lisa Lock, Andrew Zinin Verified
| Medical Xpress Verified
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal.
Open in Who Shared View Duplicates (4) Issue with article?

New method separates brain signals to show how complex actions are organized

|
By Olivia Dimmer
| MSN Verified
Olivia Dimmer A new Northwestern Medicine study has introduced a novel machine learning method for analyzing how the brain organizes complex behaviors, offering fresh evidence that neural activity is built from reusable "building blocks." The study is published in Neuron Subscribe to our newsletter for the latest sci-tech news updates.
Open in Who Shared Issue with article?

Signaling pathway may help predict immunotherapy response in glioblastoma

|
By Olivia Dimmer
| MSN Verified
Olivia Dimmer Northwestern Medicine scientists have uncovered a biological mechanism that helps explain why most patients with glioblastoma fail to respond to immunotherapy, according to their study published in Nature Communications Subscribe to our newsletter for the latest sci-tech news updates. Glioblastoma (GBM) remains one of the deadliest forms of cancer, with few effective treatment options once tumors recur.
Open in Who Shared View Duplicates (5) Issue with article?
See all 733 licensed articles (780 Total)